- Treasury Set to Unveil PPIP; Ross, GE Capital Participate
- UK Freezes $100 Million in Stanford-Linked Assets
- Iraq Historic Oil & Gas Auction Off to Shaky Start
- Madoff Investors Were 'Greedy': Hedge Fund Manager
- GM Close to Opel Deal with RHJ: Report
- After Hours Highlights: Ford, HRB, AIG, Paulson
- Britain's Queen Will Run Out of Money by 2012: Report
- J&J Unit Wins $1.67 Billion Verdict Against Abbott Labs
- Buffett in Belt, Suspenders as Tide Went Out: Analyst
- Wall Street's Fear Gauge Suggests Worst is Over
- Yoshikami: July Earnings BETTER Be Better
- Art Cashin: Here's When Rallies Die
- Top Strategists' Plays for the Second Half
- The "New" Michael Jackson Fortune
- Hollywood Cashing In On Financial Crisis
- Warren Buffett Wearing "Belt and Suspenders" As Tide Went Out - KBW Analyst
- Winners & Losers Since March 9th Low
- Sports Poker Event Trying To Buck Recession
- New Mumbai bridge to open after a decade of delay
- Conoco refuses to lower Bai Hassan bid
- Ahead of the Bell: Consumer confidence
- UK agency freezes $100 mln in Allen Stanford case
- Taiwan opens door for Chinese investment
- Turkish economy shrank 13.8 percent in Q1
- Wall-to-wall media coverage of Jackson receding
- Iraq's Zubair field draws 4 bids
- American Airlines to shut down Conn. call center
Text Size 
WHITEHOUSE STATION, N.J. - Merck & Co. said Monday it entered a partnership with Drugs for Neglected Disease initiative and will license to the institute drug candidates for tropical diseases that have no cure, or for which treatment could be improved.
The agreement covers drug candidates for illnesses like visceral leishmaniasis and Chagas disease, potentially lethal parasitic illnesses spread by insects. Current treatment for those illnesses may be toxic, or very expensive, or difficult to administer, Merck said.
Merck will give DNDi non-exclusive licenses for the drugs, meaning it can enter into other partnerships as well, and Merck will have the option to pursue late clinical development. DNDi, a not-for-profit foundation, will have joint intellectual property rights and will not have to make license payments on the drugs if they are approved for sale.
In afternoon trading, Merck shares gave up 65 cents, or 2.5 percent, to $25.26.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes